Price$86.05-2.12 (-2.40%)
01:30 PM07:45 PM
News · 26 weeks77-62%
2026-04-192026-10-11
Mix3190d
- Insider17(55%)
- Other5(16%)
- SEC Filings4(13%)
- Earnings2(6%)
- Leadership2(6%)
- Analyst1(3%)
Latest news
25 items- PRLandmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on InsulinPublication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category. Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care. Benefits observed across a broad range of participants, including those taking GLP-1 medications.1 Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced that r
- ANALYSTBarclays initiated coverage on Dexcom with a new price targetBarclays initiated coverage of Dexcom with a rating of Overweight and set a new price target of $115.00
- PRDexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern TimeDexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the sta
- PRDexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is FadingFirst-of-its-kind NIL program features 27 athletes with Type 1 diabetes across 13 sports, marking the program’s largest roster to dateDexcom will host "Dexcom U Days" this fall to drive meaningful community and mentorship between college and young athletes with diabetesNew research shows young adults with Type 1 diabetes are sticking with sports longer and feeling less isolated than they did since the launch of Dexcom U in 20221DEXCOM, INC. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.This press release featur
- INSIDEREVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes CareNew global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1 New partnership reinforces Dexcom’s commitment to advancing Type 1 diabetes care. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. This press release features mult
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- PRDexcom Promotes Jereme Sylvain to Chief Operating OfficerDexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcom’s global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence. Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership team and guided the c
- INSIDEREVP, Chief Financal Officer Sylvain Jereme M sold $302,936 worth of shares (3,638 units at $83.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 146,828 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Boehnlein Glenn S was granted 5,841 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERNew insider Boehnlein Glenn S claimed ownership of 42 shares (SEC Form 3)3 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- PRDexcom Appoints Glenn Boehnlein to Board of DirectorsDexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology companies, where he helped guide the organization through a period of significant growth, innovation, and global expansion. Mr. Boehnlein brings to the Dexcom Board expertise in financial leadership, capital allocation, strate
- PRDexcom Announces Upcoming Conference PresentationDexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live presentation is scheduled to begin at approximately 8:00 AM EDT and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed ho
- INSIDEREVP Chief People & Culture Off Stern Sadie sold $226,669 worth of shares (2,565 units at $88.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 126,043 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERPresident, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERExecutive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Augustinos Nicholas gifted 1,075 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
DXCM FAQ
7 questionsWhat does DexCom Inc. do?
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop...Where does DXCM stock trade?
DexCom Inc. (DXCM) is listed on NASDAQ.What sector and industry is DXCM in?
DexCom Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did DexCom Inc. go public?
DexCom Inc. (DXCM) completed its IPO in 2005.What are analysts saying about DXCM?
DexCom Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-10-07.What companies are similar to DXCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DXCM side-by-side with any of them on Quantisnow.How can I track DXCM on Quantisnow?
Quantisnow aggregates DexCom Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXCM to receive live email and push alerts on every new disclosure.